Benzinga | Sep 8, 2021 04:03PM EDT

UPDATE: Cardiff Says 42% Of Patients Treater Per Protocol At Recommend Dose Who Were Evaluable For Disease Response As Of Cut-Off Achieved A Partial Response

* 8 of 19 (42%) patients treated per protocol at the recommended Phase 2 dose (RP2D) of onvansertib 15 mg/m2 who were evaluable for disease response as of the data cut-off achieved a partial response (PR). Historically, objective response rates (ORR) of 5-13% have been reported in a similar patient population treated with standard of care chemotherapy1-4